Cargando…

Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis

This study aimed to identify the pathological outcomes and survival benefits of neoadjuvant hormone therapy (NHT) combined with radical prostatectomy (RP) and radiotherapy (RT) administered to patients with high-risk prostate cancer (HRPCa). We searched PubMed, Embase, and the Cochrane Library for s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Wen, Yao, Yu, Liu, Xue, Liu, Yong, Zhang, Gui-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269824/ https://www.ncbi.nlm.nih.gov/pubmed/33586699 http://dx.doi.org/10.4103/aja.aja_96_20

Ejemplares similares

Neoadjuvant Therapy in High-Risk Prostate Cancer
por: Ashrafi, Akbar N., et al.
Publicado: (2020)

Short-term benefit of neoadjuvant hormone therapy in patients with localized high-risk or limited progressive prostate cancer
por: Ma, Bing-Lei, et al.
Publicado: (2019)

Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer
por: Sugino, Fumiya, et al.
Publicado: (2023)

Neoadjuvant hormone therapy following treatment with robotic-assisted radical prostatectomy achieved favorable in high-risk prostate cancer
por: Hou, Cheng-Pang, et al.
Publicado: (2014)

Neoadjuvant Chemohormonal Therapy in Prostate Cancer Before Radical Prostatectomy: A Systematic Review and Meta-Analysis
por: Ge, Qingyu, et al.
Publicado: (2022)

The Impact of Neoadjuvant Hormone Therapy on Surgical and Oncological Outcomes for Patients With Prostate Cancer Before Radical Prostatectomy: A Systematic Review and Meta-Analysis
por: Zhang, Lijin, et al.
Publicado: (2021)

Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: A systematic review and meta-analysis
por: Li, Yongzheng, et al.
Publicado: (2022)

The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer
por: Joung, Jae Young, et al.
Publicado: (2015)

Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic Review
por: Boulva, Kerianne, et al.
Publicado: (2021)

Brachytherapy Combined With or Without Hormone Therapy for Localized Prostate Cancer: A Meta-Analysis and Systematic Review
por: Zhou, Xueliang, et al.
Publicado: (2020)

Clinical Analysis of Perioperative Outcomes on Neoadjuvant Hormone Therapy before Laparoscopic and Robot-Assisted Surgery for Localized High-Risk Prostate Cancer in a Chinese Cohort
por: Sun, Guangyu, et al.
Publicado: (2022)

Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis
por: Ma, Hong-Fang, et al.
Publicado: (2023)

Neoadjuvant chemotherapy for high‐risk prostatic adenocarcinoma
por: Brunner, Robert, et al.
Publicado: (2019)

Comparing outcomes between neoadjuvant hormonal therapy followed by prostatectomy versus upfront prostatectomy in high-risk prostate cancer: The road ahead
por: Bhargava, Priyank
Publicado: (2023)

Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations
por: Chi, Chenfei, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer: A Systematic Review
por: Sfoungaristos, Stavros, et al.
Publicado: (2013)

Prostate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal Therapy
por: Kim, Sung Han, et al.
Publicado: (2016)

Hormonal Therapy for Infantile Spasms: A Systematic Review and Meta-Analysis
por: Guang, Shiqi, et al.
Publicado: (2022)

Neoadjuvant therapy in pancreatic cancer: a systematic review and meta‐analysis of prospective studies
por: Zhan, Han‐Xiang, et al.
Publicado: (2017)

Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy
por: Kang, Yong Jin, et al.
Publicado: (2017)

Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis
por: Qin, Hao, et al.
Publicado: (2023)

Comparative Efficacy of Combined Radiotherapy, Systemic Therapy, and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-Analysis and Systematic Review
por: Wang, Yuhan, et al.
Publicado: (2020)

Neoadjuvant chemotherapy before radical prostatectomy for locally advanced prostate cancer: Protocol for a systematic review and meta-analysis
por: Lin, Tianhai, et al.
Publicado: (2019)

Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma
por: Zhou, Yao-Yao, et al.
Publicado: (2016)

Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer
por: Lei, Jun H., et al.
Publicado: (2015)

Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis
por: Lin, Ying-Yi, et al.
Publicado: (2022)

Menopausal hormone therapy does not improve some domains of memory: A systematic review and meta-analysis
por: Chen, Lin, et al.
Publicado: (2022)

Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis
por: Liu, Miao, et al.
Publicado: (2021)

Total neoadjuvant therapy or standard chemoradiotherapy for locally advanced rectal cancer: A systematic review and meta-analysis
por: Ma, Zhou, et al.
Publicado: (2022)

Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis
por: Jian, Tengteng, et al.
Publicado: (2022)

The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis
por: Chen, Junru, et al.
Publicado: (2018)

Neoadjuvant Chemotherapy for Different Stages of Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis
por: Liu, Shuai, et al.
Publicado: (2022)

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis
por: Burdett, Sarah, et al.
Publicado: (2019)

Combination therapy for high-volume versus low-volume metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis
por: Jian, Tengteng, et al.
Publicado: (2023)

Consumption of flavonoids and risk of hormone-related cancers: a systematic review and meta-analysis of observational studies
por: Liu, Fubin, et al.
Publicado: (2022)

Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis
por: Malthaner, Richard A, et al.
Publicado: (2004)

Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer
por: Sasaki, Takeshi, et al.
Publicado: (2021)

Clinical efficacy of neoadjuvant chemohormonal therapy combined with laparoscopic radical prostatectomy in high-risk Prostate Cancer
por: Zhang, Peng, et al.
Publicado: (2022)

Kuntai Capsule plus Hormone Therapy vs. Hormone Therapy Alone in Patients with Premature Ovarian Failure: A Systematic Review and Meta-Analysis
por: Liu, Weiping, et al.
Publicado: (2019)

Comparison of doublet and triplet therapies for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis
por: Wang, Lei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gssu5kejbn2807mhd7hhcuiukt